PRANAV BARVE: Open Payments
NPI 1972899839 · WILDOMAR, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,723 in 84 payments from 27 companies in 2025. Trend: 2023 $2,480 · 2024 $2,325 · 2025 $1,723
Food & beverage: $1,723
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 8 | $196 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $161 |
| Sumitomo Pharma America, Inc. | 8 | $160 |
| Corcept Therapeutics | 9 | $155 |
| Amgen Inc. | 9 | $140 |
| Dexcom, Inc. | 5 | $114 |
| Novartis Pharmaceuticals Corporation | 5 | $101 |
| Lundbeck LLC | 4 | $71 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $63 |
| Kowa Pharmaceuticals America, Inc. | 4 | $61 |
Products named: REXULTI, CAPLYTA, GEMTESA, Korlym, Dexcom G6 Transmitter, LEQVIO, OTEZLA, JARDIANCE.
Industry payments across CA — which companies pay providers there.
